Skip to content

Hemoporfin Photodynamic Therapy for Port wine Stain

Efficacy and safety of hemoporfin in photodynamic therapy for port-wine stain

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OIh-17011454
Enrollment
Unknown
Registered
2017-05-21
Start date
2017-06-01
Completion date
Unknown
Last updated
2017-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

port wine stain

Interventions

Observation group:Hemoporfin Photodynamic Therapy

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. clinical diagnosis of PWS patients; 2. patients aged 1~65 years; 3.The subjects instructions have been read, willing and able to respond to the requirements of the program and receive follow-up visits; 4. Agree to sign written informed consent;

Exclusion criteria

Exclusion criteria: 1. The affected area is accompanied by other obvious skin diseases that may affect efficacy such as severe acne,contact dermatitis and pyogenic infection; 2. The treatment area was treated with isotope therapy, photodynamic therapy, or other treatments that might affect efficacy evaluation; 3. Currently suffering from allergic diseases; Known to suffer from skin allergies, light porphyria patients or known to test drug (porphyrin) and its chemical structure is similar to drug allergy; 4. person who has a scar constitution or has a tendency to scar; 5. Within 1 months of application of photosensitive drug known as griseofulvin, thiazide diuretics, sulfonylurea, phenothiazine, sulfa drugs, vitamin A acid, quinolones and tetracyclines in patients; 6. Known as severe immune dysfunction, or the need for long-term use of glucocorticoids and immunosuppressive agents; 7. Electrocardiographic abnormalities, organic heart disease; 8. Abnormal liver function (ALT and AST exceeded the normal value limit, TBIL exceeded 1.5 times the normal value limit) or severe renal dysfunction (renal function index exceeded the normal value of 1.5 times the upper limit); 9. One who has inherited or acquired coagulopathy or who is taking anticoagulant drugs; 10. Suffering from serious neurological, mental and endocrine disorders.

Design outcomes

Primary

MeasureTime frame
Visual analog pain score;Investigators' subjective assessment;Patients' subjective assessment;

Secondary

MeasureTime frame
skin thickness;hyporchoic band thickness;Adler grade of blood flow;shearwave velocity;Young's modulus;Vascular density;

Countries

China

Contacts

Public ContactJiang Xian

West China Hospital, Sichuan University

jennyxianj@163.com+86 028-85423319

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026